AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)‘s stock had its “outperform” rating reaffirmed by investment analysts at FBR & Co in a research note issued on Saturday. They currently have a $3.00 target price on the biopharmaceutical company’s stock. FBR & Co’s price objective points to a potential upside of 417.15% from the stock’s current price.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 1.6780% on Friday, reaching $0.5801. 469,257 shares of the company traded hands. The stock has a 50-day moving average price of $0.72 and a 200 day moving average price of $0.68. The firm’s market capitalization is $44.01 million. AVEO Pharmaceuticals has a 1-year low of $0.50 and a 1-year high of $1.15.
TRADEMARK VIOLATION WARNING: “FBR & Co Reiterates “Outperform” Rating for AVEO Pharmaceuticals, Inc. (AVEO)” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/04/21/aveo-pharmaceuticals-aveo-outperform-rating-reiterated-at-fbr-co-updated-updated.html.
In related news, major shareholder Equity Opportunities Iv Growth bought 6,000,000 shares of the stock in a transaction on Tuesday, March 28th. The stock was bought at an average price of $0.50 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.10% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Sarissa Capital Management LP bought a new position in shares of AVEO Pharmaceuticals during the fourth quarter valued at $917,000. New Leaf Venture Partners L.L.C. acquired a new position in AVEO Pharmaceuticals during the fourth quarter valued at approximately $1,399,000. Renaissance Technologies LLC raised its position in AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new position in AVEO Pharmaceuticals during the fourth quarter valued at approximately $1,678,000. 37.94% of the stock is owned by institutional investors.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.